Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 6/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | JAK3 | P52333 | 5/20 | 0.52 |
| ▸ | BTK | Q06187 | 4/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370532 | 0.94 | MAP3K7 (0.66) | MAP3K7MAP2K1MAPK1FLT3EGFR | |
| SCHEMBL30672750 | 0.94 | MAP3K7 (0.66) | MAP3K7MAP2K1MAPK1FLT3EGFR | |
| SCHEMBL16391080 | 0.88 | EGFR (0.65) | EGFRJAK3BTKJAK2JAK1 | |
| SCHEMBL16370819 | 0.86 | SRC (0.53) | MAP3K7MAP2K1MAPK1FLT3EGFR | |
| SCHEMBL30672740 | 0.86 | SRC (0.53) | MAP3K7MAP2K1MAPK1FLT3EGFR | |
| SCHEMBL16370374 | 0.84 | EGFR (0.63) | MAP3K7MAP2K1MAPK1FLT3EGFR | |
| SCHEMBL16391116 | 0.82 | EGFR (0.72) | EGFRJAK3BTKITK | |
| SCHEMBL16391089 | 0.81 | JAK3 (0.60) | EGFRJAK3BTKITK | |
| SCHEMBL28561697 | 0.79 | MAP3K7 (0.63) | MAP3K7MAP2K1MAPK1FLT3EGFR | |
| SCHEMBL16391084 | 0.79 | EGFR (0.69) | EGFRJAK3BTKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112592334-B | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-112592334-A | Pyrimidine derivatives as kinase inhibitors | 艾森生物科学公司 | 2021-04-02 | — | — | CN | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2018-09-06 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-3019496-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Biosciences, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| WO-2015006754-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | MAP3K7 204/4885MAP2K1 160/4885MAPK1 357/4885 |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | MAP3K7 204/4885MAP2K1 160/4885MAPK1 357/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | MAP3K7 204/4885MAP2K1 160/4885MAPK1 357/4885 |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | MAP3K7 204/4885MAP2K1 160/4885MAPK1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.